123 related articles for article (PubMed ID: 10470237)
1. Liaison free PSA--an automated chemiluminescent immunoassay for the determination of free prostate specific antigen (fPSA).
König B; Ivankovic B; Schleff R; Mack M
Anticancer Res; 1999; 19(4A):2763-5. PubMed ID: 10470237
[TBL] [Abstract][Full Text] [Related]
2. LIAISON hCG--an automated chemiluminescent immunoassay for the determination of human chorionic gonadotropin (hCG).
Oed M; Amtmann R; Löwer Y; Schlett R; Mack M
Anticancer Res; 1999; 19(4A):2735-7. PubMed ID: 10470231
[TBL] [Abstract][Full Text] [Related]
3. LIAISON Ferritin--an automated chemiluminescent immunoassay for the determination of Ferritin.
König B; Oed M; Kunz A; Schlett R; Mack M
Anticancer Res; 1999; 19(4A):2739-41. PubMed ID: 10470232
[TBL] [Abstract][Full Text] [Related]
4. Automated Cobas Core PSA assays: sensitive, precise, and specific measurement of PSA-total and PSA-total/PSA-free ratio.
Groche D; Trebo R; Peters I; Pfleiderer P
Anticancer Res; 1999; 19(4A):2767-70. PubMed ID: 10470238
[TBL] [Abstract][Full Text] [Related]
5. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
6. Early detection of prostate cancer: is PSA a reliable option?
Okihara K; Babaian RJ
Tex Med; 2001 Feb; 97(2):59-62. PubMed ID: 11233061
[TBL] [Abstract][Full Text] [Related]
7. External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser.
Molina R; Bonfrer J; Banfi G; Bugugnani MJ; Cornu F; Hannemann-Pohl K; Hubl W; Merz O; Bach M; Mack M
Clin Lab; 2000; 46(3-4):169-79. PubMed ID: 10791126
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
[TBL] [Abstract][Full Text] [Related]
9. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
Slev PR; La'ulu SL; Roberts WL
Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
[TBL] [Abstract][Full Text] [Related]
10. Development of a new automated enzyme immunoassay for the determination of neuron-specific enolase.
Sterk M; Oenings A; Eymann E; Roos W
Anticancer Res; 1999; 19(4A):2759-62. PubMed ID: 10470236
[TBL] [Abstract][Full Text] [Related]
11. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
12. [Parameters of PSA fractions in early diagnosis of prostatic cancer in healthy males over 50].
Loran OB; Krokhotina LV; Pushkar' DIu; Valiev AZ; Rasner PI
Urol Nefrol (Mosk); 1999; (1):19-21. PubMed ID: 11149339
[TBL] [Abstract][Full Text] [Related]
13. Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500.
Zur B; Holdenrieder S; Walgenbach-Brünagel G; Albers E; Stoffel-Wagner B
Clin Lab; 2012; 58(1-2):97-105. PubMed ID: 22372351
[TBL] [Abstract][Full Text] [Related]
14. One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum.
Fernández-Sánchez C; McNeil CJ; Rawson K; Nilsson O; Leung HY; Gnanapragasam V
J Immunol Methods; 2005 Dec; 307(1-2):1-12. PubMed ID: 16277989
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
16. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
17. Performance characteristics of IMMULITE TPS: a comparison with TPS IRMA.
Einarsson R; Lei JD; Ullrich A; Van Dalen A
Anticancer Res; 1999; 19(4A):2743-7. PubMed ID: 10470233
[TBL] [Abstract][Full Text] [Related]
18. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
19. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
20. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
Canto EI; Singh H; Shariat SF; Kadmon D; Miles BJ; Wheeler TM; Slawin KM
J Urol; 2004 Sep; 172(3):900-4. PubMed ID: 15310993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
